Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient

Clin Pharmacol Ther. 2005 Sep;78(3):309-10. doi: 10.1016/j.clpt.2005.06.005.
No abstract available

Publication types

  • Comment
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Area Under Curve
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Biotransformation
  • Celecoxib
  • Child
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / pharmacokinetics*
  • Cytochrome P-450 CYP2C9
  • Genotype
  • Humans
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Pyrazoles / adverse effects*
  • Pyrazoles / pharmacokinetics*
  • Sulfonamides / adverse effects*
  • Sulfonamides / pharmacokinetics*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Membrane Proteins
  • Pyrazoles
  • Sulfonamides
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Celecoxib